Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
Eun Jin KimSun Ha ChoiJae Seok ParkYong Shik KwonJaehee LeeYeonjae KimShin-Yup LeeEun Young ChoiPublished in: Yonsei medical journal (2020)
We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800-150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04-0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01-0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
Keyphrases
- sars cov
- intensive care unit
- respiratory syndrome coronavirus
- newly diagnosed
- hiv infected patients
- stem cells
- cardiovascular disease
- risk factors
- cardiovascular events
- patient reported outcomes
- coronary artery disease
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- antiretroviral therapy
- data analysis